I’m gonna be write about the 2019 Atrial Fibrillation Guideline updates. For those of you not aware, we have major cardiology groups and other physiology groups like the American College of Cardiology and the Heart Rhythm Society, which every few years, release joint statements about how to manage atrial fibrillation. They usually incorporate things that have had major changes that can influence and management of patients with atrial fibrillation. And so in 2019, they released a focused update. It’s not a complete overhaul of the guidelines, but it did emphasize some new treatment options or new treatment options and new treatment guidelines for doctors and patients out there, which I wanted to emphasize to you today. So the first thing in the guideline was that changes into blood thinners that the newer category of blood thinners, sometimes called NOACs or DOACs, which includes new blood thinners, like Eliquis or Xarelto or Pradaxa or Savaysa, are now preferred over warfarin, meani...